2016. "Disclosures", Diabetes Risks from Prescription & Non Prescription Drugs: Mechanisms and Approaches to Risk Reduction, Sam Dagogo-Jack, MD
Download citation file:
Dr. Dagogo-Jack is a principal investigator or coinvestigator for clinical trials contracts between the University of Tennessee and AstraZeneca, Novo Nordisk, and Boehringer-Ingelheim and has served as a consultant and an advisory board member for Merck, Novo Nordisk, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKline, Sanofi, and Janssen Pharmaceuticals. He also has served as an expert for Sidley Austin, and Adam and Reese, on diabetes-related litigation.